Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

T vs. C	Standard of Care (SoC)	cetuximab plus platin plus 5FU	durvalumab alone	tremelimumab	nivolumab alone	pembrolizumab alone	durvalumab plus tremelimumab	pembrolizumab plus 5FU plus platin
Standard of Care (SoC)	---	1.00 0.81; 1.23	1.10 0.91; 1.33	0.72 0.48; 1.07	1.43 1.03; 1.97	1.29 1.10; 1.52	0.99 0.82; 1.20	1.47 1.15; 1.88
cetuximab plus platin plus 5FU	1.00 0.82; 1.23	---	1.10 0.83; 1.46	0.72 0.46; 1.13	1.43 0.98; 2.10	1.30 1.14; 1.47	1.00 0.75; 1.32	1.47 1.29; 1.68
durvalumab alone	0.91 0.75; 1.10	0.91 0.69; 1.20	---	0.65 0.43; 1.00	1.30 0.90; 1.90	1.18 0.92; 1.52	0.91 0.72; 1.14	1.34 0.98; 1.83
tremelimumab	1.40 0.93; 2.09	1.39 0.88; 2.19	1.53 1.00; 2.35	---	1.99 1.19; 3.35	1.81 1.17; 2.79	1.39 0.97; 1.99	2.05 1.28; 3.29
nivolumab alone	0.70 0.51; 0.97	0.70 0.48; 1.02	0.77 0.53; 1.12	0.50 0.30; 0.84	---	0.91 0.63; 1.30	0.70 0.48; 1.01	1.03 0.68; 1.54
pembrolizumab alone	0.77 0.66; 0.91	0.77 0.68; 0.88	0.85 0.66; 1.09	0.55 0.36; 0.86	1.10 0.77; 1.59	---	0.77 0.60; 0.99	1.13 0.94; 1.37
durvalumab plus tremelimumab	1.01 0.83; 1.21	1.00 0.76; 1.32	1.10 0.87; 1.39	0.72 0.50; 1.03	1.44 0.99; 2.09	1.30 1.02; 1.67	---	1.47 1.08; 2.01
pembrolizumab plus 5FU plus platin	0.68 0.53; 0.87	0.68 0.59; 0.78	0.75 0.55; 1.02	0.49 0.30; 0.78	0.97 0.65; 1.46	0.88 0.73; 1.06	0.68 0.50; 0.92	---

pathologies: 276,103,277,102,109,278,101,192,114 - treatments: 875 result logic